Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AGXT | P21549 | 5/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408827 | 0.90 | TRPV1 (0.34) | TSHRCA1CA2P2RX7KDM4E | |
| SCHEMBL10735462 | 0.90 | LTA4H (0.41) | CA1CA2AGXTIDO1HPGD | |
| SCHEMBL21316226 | 0.89 | KDM4E (0.39) | TSHRCA1CA2KDM4ETHRB | |
| SCHEMBL133476 | 0.87 | TSHR (0.48) | TSHRCA1CA2P2RX7KDM4E | |
| SCHEMBL27667692 | 0.85 | TSHR (0.52) | TSHRCA1CA2AGXTIDO1 | |
| Ether SCHEMBL8429378 | 0.85 | PTGS2 (0.36) | TSHRCA1CA2KDM4ETHRB | |
| SCHEMBL2655920 | 0.81 | IDO1 (0.54) | P2RX7KDM4ETHRBTDP1AGXT | |
| SCHEMBL8750395 | 0.80 | TP53 (0.43) | TSHRCA2TDP1KCNH2HPGD | |
| SCHEMBL1337544 | 0.80 | AGXT (0.43) | TSHRAGXTIDO1KCNH2 | |
| Ether SCHEMBL28044990 | 0.79 | TDP1 (0.49) | P2RX7KDM4ETHRBTDP1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| CN-101068797-A | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| CN-1040318-C | Synthesis of p-alkoxymethyl benzyl dihalochrysanthemate | UNIV HUADONG (CN) | 1998-10-21 | — | — | CN | disclosed |
| CN-1110271-A | Synthesis of p-alkoxyl-methyl-benzyl dihalo-chrysanthemate | UNIV HUADONG (CN) | 1995-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | TSHR 630/4885CA1 3375/4885CA2 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.